nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A5—Dactinomycin—testicular cancer	0.439	0.805	CbGbCtD
Methamphetamine—CYP2D6—Vinblastine—testicular cancer	0.0657	0.121	CbGbCtD
Methamphetamine—CYP2D6—Doxorubicin—testicular cancer	0.0404	0.0741	CbGbCtD
Methamphetamine—SLC18A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0299	0.134	CbGpPWpGaD
Methamphetamine—SLC18A1—lymph node—testicular cancer	0.018	0.0776	CbGeAlD
Methamphetamine—TAAR1—G alpha (s) signalling events—INSL3—testicular cancer	0.0171	0.0763	CbGpPWpGaD
Methamphetamine—SLC18A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0136	0.0608	CbGpPWpGaD
Methamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0122	0.0546	CbGpPWpGaD
Methamphetamine—SLC22A3—embryo—testicular cancer	0.0115	0.0498	CbGeAlD
Methamphetamine—SLC22A3—seminal vesicle—testicular cancer	0.0108	0.0468	CbGeAlD
Methamphetamine—MAOB—embryo—testicular cancer	0.0107	0.0461	CbGeAlD
Methamphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0106	0.0472	CbGpPWpGaD
Methamphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0105	0.0471	CbGpPWpGaD
Methamphetamine—MAOB—seminal vesicle—testicular cancer	0.01	0.0433	CbGeAlD
Methamphetamine—MAOA—embryo—testicular cancer	0.0091	0.0393	CbGeAlD
Methamphetamine—MAOA—seminal vesicle—testicular cancer	0.00855	0.0369	CbGeAlD
Methamphetamine—ADRA2C—seminal vesicle—testicular cancer	0.00822	0.0355	CbGeAlD
Methamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00822	0.0368	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00814	0.0364	CbGpPWpGaD
Methamphetamine—SLC18A2—testis—testicular cancer	0.00792	0.0342	CbGeAlD
Methamphetamine—SLC22A5—seminal vesicle—testicular cancer	0.00787	0.034	CbGeAlD
Methamphetamine—SLC22A3—gonad—testicular cancer	0.00783	0.0338	CbGeAlD
Methamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00728	0.0326	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00691	0.0309	CbGpPWpGaD
Methamphetamine—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.00689	0.0308	CbGpPWpGaD
Methamphetamine—SLC6A2—gonad—testicular cancer	0.00671	0.029	CbGeAlD
Methamphetamine—ADRA2A—seminal vesicle—testicular cancer	0.00656	0.0283	CbGeAlD
Methamphetamine—SLC22A3—female gonad—testicular cancer	0.00636	0.0275	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—INSL3—testicular cancer	0.0062	0.0277	CbGpPWpGaD
Methamphetamine—SLC6A3—testis—testicular cancer	0.00599	0.0259	CbGeAlD
Methamphetamine—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.00593	0.0265	CbGpPWpGaD
Methamphetamine—MAOB—female gonad—testicular cancer	0.00589	0.0254	CbGeAlD
Methamphetamine—SLC18A2—lymph node—testicular cancer	0.00574	0.0248	CbGeAlD
Methamphetamine—SLC22A3—testis—testicular cancer	0.00564	0.0244	CbGeAlD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00555	0.0248	CbGpPWpGaD
Methamphetamine—SLC6A3—NRF2 pathway—SLC2A6—testicular cancer	0.00525	0.0235	CbGpPWpGaD
Methamphetamine—MAOB—testis—testicular cancer	0.00522	0.0225	CbGeAlD
Methamphetamine—MAOA—female gonad—testicular cancer	0.00502	0.0217	CbGeAlD
Methamphetamine—SLC6A2—testis—testicular cancer	0.00483	0.0209	CbGeAlD
Methamphetamine—ADRA2C—female gonad—testicular cancer	0.00483	0.0208	CbGeAlD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0048	0.0215	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00478	0.0214	CbGpPWpGaD
Methamphetamine—ADRA2A—gonad—testicular cancer	0.00474	0.0205	CbGeAlD
Methamphetamine—SLC22A5—female gonad—testicular cancer	0.00462	0.02	CbGeAlD
Methamphetamine—MAOA—testis—testicular cancer	0.00445	0.0192	CbGeAlD
Methamphetamine—ADRA2C—testis—testicular cancer	0.00428	0.0185	CbGeAlD
Methamphetamine—SLC22A5—testis—testicular cancer	0.0041	0.0177	CbGeAlD
Methamphetamine—SLC22A3—lymph node—testicular cancer	0.00409	0.0177	CbGeAlD
Methamphetamine—ADRA2A—female gonad—testicular cancer	0.00385	0.0166	CbGeAlD
Methamphetamine—MAOB—lymph node—testicular cancer	0.00378	0.0163	CbGeAlD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00374	0.0167	CbGpPWpGaD
Methamphetamine—SLC6A2—lymph node—testicular cancer	0.0035	0.0151	CbGeAlD
Methamphetamine—TAAR1—GPCR downstream signaling—INSL3—testicular cancer	0.0035	0.0157	CbGpPWpGaD
Methamphetamine—ADRA2A—testis—testicular cancer	0.00342	0.0148	CbGeAlD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00331	0.0148	CbGpPWpGaD
Methamphetamine—MAOA—lymph node—testicular cancer	0.00323	0.0139	CbGeAlD
Methamphetamine—TAAR1—Signaling by GPCR—INSL3—testicular cancer	0.00318	0.0142	CbGpPWpGaD
Methamphetamine—ADRA2C—lymph node—testicular cancer	0.0031	0.0134	CbGeAlD
Methamphetamine—CYP2D6—female gonad—testicular cancer	0.00298	0.0129	CbGeAlD
Methamphetamine—SLC22A5—lymph node—testicular cancer	0.00297	0.0128	CbGeAlD
Methamphetamine—MAOB—Biological oxidations—HPGDS—testicular cancer	0.00287	0.0128	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00282	0.0126	CbGpPWpGaD
Methamphetamine—CYP2D6—testis—testicular cancer	0.00265	0.0114	CbGeAlD
Methamphetamine—ADRA2A—lymph node—testicular cancer	0.00248	0.0107	CbGeAlD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00244	0.0109	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00243	0.0109	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00224	0.01	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00209	0.00935	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0019	0.00849	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—INSL3—testicular cancer	0.00188	0.0084	CbGpPWpGaD
Methamphetamine—MAOA—Biological oxidations—HPGDS—testicular cancer	0.0018	0.00804	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.00171	0.00763	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.0017	0.0076	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00168	0.00752	CbGpPWpGaD
Methamphetamine—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.00161	0.00719	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.00159	0.00712	CbGpPWpGaD
Methamphetamine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.00131	0.00584	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.00129	0.00579	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	0.000964	0.00431	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	0.0009	0.00403	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	0.000875	0.00391	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	0.000817	0.00366	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000783	0.0035	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.000731	0.00327	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	0.000664	0.00297	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—H2AFZ—testicular cancer	0.000601	0.00269	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—STK11—testicular cancer	0.000598	0.00267	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—KITLG—testicular cancer	0.000553	0.00247	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INSL3—testicular cancer	0.000517	0.00231	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—HPGDS—testicular cancer	0.00049	0.00219	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INSL3—testicular cancer	0.000483	0.00216	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—HPGDS—testicular cancer	0.000415	0.00185	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—FGFR3—testicular cancer	0.000411	0.00184	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	0.000392	0.00175	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—KIT—testicular cancer	0.000378	0.00169	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—STK11—testicular cancer	0.000356	0.00159	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—HPGDS—testicular cancer	0.000308	0.00138	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—STK11—testicular cancer	0.000301	0.00135	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—HPGDS—testicular cancer	0.000253	0.00113	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—STK11—testicular cancer	0.000223	0.000999	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HPGDS—testicular cancer	0.000205	0.000919	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—STK11—testicular cancer	0.000184	0.000822	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	0.000165	0.00074	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STK11—testicular cancer	0.000165	0.000736	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	0.000155	0.000691	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STK11—testicular cancer	0.000154	0.000687	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KITLG—testicular cancer	0.000152	0.000681	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—STK11—testicular cancer	0.000149	0.000668	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KITLG—testicular cancer	0.000142	0.000636	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HPGDS—testicular cancer	0.000134	0.000599	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	0.000126	0.000561	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STK11—testicular cancer	0.000125	0.000558	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	0.000116	0.000517	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	0.000113	0.000506	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	0.000106	0.000473	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIT—testicular cancer	0.000104	0.000465	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—STK11—testicular cancer	9.73e-05	0.000435	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIT—testicular cancer	9.7e-05	0.000434	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	8.58e-05	0.000384	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIT—testicular cancer	7.88e-05	0.000352	CbGpPWpGaD
